P - Caution when used during pregnancy
L - Caution when used during lactation
FI - Food*
LI - Lab*
Cefpodoxime (marketed as the prodrug cefpodoxime proxetil by Pharmacia & Upjohn under the trade name Vantin and under the name Orelox by Sanofi-Aventis), is an oral third generation cephalosporin. It is active against most Gram positive and Gram negative organisms. Notable exceptions include Pseudomonas aeruginosa, Enterococcus, and Bacteroides fragilis. It is commonly used to treat acute otitis media, pharyngitis, and sinusitis. It also finds use as oral continuation therapy when intravenous cephalosporins (such as ceftriaxone) are no longer necessary for continued treatment.
Cefpodoxime binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
Absorption
Decreased absorption in conditions of low gastric acidity. Bioavailability: about 50%.
Distribution
Respiratory and GU tract (therapeutic concentrations); enters breast milk (low concentrations). Protein-binding: 20-30%.
Metabolism
De-esterified to cefpodoxime in the intestinal lumen.
Excretion
Via the urine (as unchanged); removed by dialysis; 2-3 hours (elimination half-life); prolonged in renal impariment.
Information Not Available
Anaphylactic shock; purpuric nephritis, skin rash, pruritus; diarrhoea, nausea, abdominal pain, vomiting.
Potentially Fatal: Pseudomembranous colitis; nephrotoxicity.
Monitor
Response to therapy
Monitor patient's response to therapy. Notify health care provider if infection does not appear to improve or worsens.
Adverse Reactions
Monitor patient for GI, DERM, and general body adverse reactions, and signs of superinfection. Inform health care provider if noted and significant. Immediately report severe diarrhea, diarrhea containing blood or pus, or severe abdominal cramping.
Overdosage
Toxic symptoms may include nausea, vomiting, epigastric distress and diarrhoea. Haemodialysis or peritoneal dialysis may aid in the removal of cefpodoxime from the body, particularly if renal function is compromised.
History of allergy to penicillin; severe renal impairment; pregnancy and lactation.
Antacids or H2-blockers may decrease the absorption of cefpodoxime. Probenecid inhibits renal excretion.
Potentially Fatal: Monitor renal function during admin. Additive nephrotoxic effects with furosemide.
Food Interaction
Food delays absorption; cefpodoxime levels may be increased with food.
Oral
Urinary tract infections
Adult: 100-200 mg every 12 hours.
Child: 8-10 mg/kg/day in 2 divided doses. Max dose: 400 mg daily.
Renal impairment: Patients on haemodialysis: Dose should be given after each dialysis session.
CrCl (ml/min) Dosage Recommendation
10-39 Increase dosing intervals to 24 hourly.
<10 Increase dosing intervals to 48 hourly.
Oral
Respiratory tract infections
Adult: 100-200 mg every 12 hours.
Child: 8-10 mg/kg/day in 2 divided doses. Max dose: 400 mg daily.
Renal impairment: Patients on haemodialysis: Dose should be given after each dialysis session.
CrCl (ml/min) Dosage Recommendation
10-39 Increase dosing intervals to 24 hourly.
<10 Increase dosing intervals to 48 hourly.
Oral
Skin infections
Adult: 200-400 mg every 12 hours.
Child: 8-10 mg/kg/day in 2 divided doses. Max dose: 400 mg/day.
Renal impairment: Patients on haemodialysis: Dose should be given after each dialysis session.
CrCl (ml/min) Dosage Recommendation
10-39 Increase dosing intervals to 24 hourly.
<10 Increase dosing intervals to 48 hourly.
Oral
Otitis media
Child: 8-10 mg/kg/day in 2 divided doses. Max dose: 400 mg daily.
Renal impairment: Patients on haemodialysis: Dose should be given after each dialysis session.
CrCl (ml/min) Dosage Recommendation
10-39 Increase dosing intervals to 24 hourly.
<10 Increase dosing intervals to 48 hourly.
Oral
Uncomplicated gonorrhoea
Adult: A single dose of 200 mg may be used.
Renal impairment: Dose reduction may be required.
Information Not Available
Caution when used during pregnancy
Caution when used during lactation
Consider benefits relative to risks. Safety and efficacy in children younger than 6 months of age not established.
Information Not Available
Hypersensitivity
Oral
Store at 20-25°C.
Oral
Store at 20-25°C.
You will hear from us only if the bid amount matches the minimum threshold and intended usage match our vision. You can resubmit another bid.